RxDoctor Payments Data

Rajbir Minhas, MD

Internal Medicine · Cincinnati, OHNPI 1134175409

Payments from drug & device makers

$61,877in general payments, 2019–2025

Across 1,126 payments — averaging $54.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$48K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Vertos Medical, Inc.$1K
  • Collegium Pharmaceutical, Inc.$1K
  • Amgen$791
  • Takeda Pharmaceuticals U.S.A., Inc.$768
  • plus $9K from 41 others

What the payments were for

  • Speaking & faculty fees$45,82074%
  • Food & beverage$15,96926%
  • Education$880%
  • Gifts$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,877 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$115,704
Medicare patients
161
Services billed
2,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant99$154,353
RelistorMethylnaltrexone Bromide25$77,419
Nurtec OdtRimegepant Sulfate47$76,830
QuliptaAtogepant55$61,094
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,396$61,072
LinzessLinaclotide103$60,867
ZtlidoLidocaine78$50,273
Aimovig AutoinjectorErenumab-Aooe63$45,264
Pregabalin1,188$34,443
Buprenorphine143$29,819
OxycontinOxycodone Hcl76$27,349
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,086$21,904
LyricaPregabalin15$20,975
Emgality PenGalcanezumab-Gnlm29$20,351
MovantikNaloxegol Oxalate48$19,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Linzess$47,628$276,315257 claims
PfizerNurtec Odt, Lyrica$670$97,80562 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$746$77,41925 claims
Scilex Pharmaceuticals Inc.Ztlido$528$50,27378 claims
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er$1,126$30,62957 claims
MerckBelsomra$228$15,02735 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$768$7,63216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →